Title:Chitosan-based Nanomedicine in the Management of Age-related Macular
Degeneration: A Review
Volume: 14
Issue: 1
Author(s): Swarupananda Mukherjee*, Dipanjan Karati, Sudarshan Singh and Bhupendra G. Prajapati*
Affiliation:
- Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata, Group of Institutions, 124, B.L Saha Road, Kolkata 700053, India
- Department of Pharmaceutical Technology, Shree S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, 384012, India
Keywords:
Chitosan, age-related macular degeneration, nanomedicine, biopolymers, drug delivery, nanocarriers.
Abstract: Age-related macular degeneration (AMD) is a leading cause of permanent blindness
globally. Due to the various obstacles, highly invasive intravitreal (IVT) injections are the primary
method used to deliver medications to the tissues of the posterior eye. An utmost patientfriendly
topical ocular delivery approach has been extensively researched in recent years. Mucoadhesive
compositions extend precorneal residence time while reducing precorneal clearance.
They increase the likelihood of adhesion to corneal and conjunctival surfaces and, as a result, allow
for enhanced delivery to the posterior eye segment. Due to its remarkable mucoadhesive
characteristics, chitosan (CS) has undergone the most extensive research of any mucoadhesive
polymer. Drug delivery to the front and back of the eye is still difficult. The pharmaceutical industry
has shown greater interest in drug delivery systems (DDSs) based on nanotechnology (NT)
in recent years, particularly those made from natural polymers like chitosan, alginate, etc. Because
of their incredible adaptability, higher biological effects, and favourable physicochemical
properties, CS-oriented nanomaterials (NMs) are explored by researchers as prospective nanocarriers.
CS are the right substrates to develop pharmaceutical products, such as hydrogels, nanoparticles
(NP), microparticles, and nanofibers, whether used alone or in composite form. CS-based
nanocarriers deliver medicine, such as peptides, growth factors, vaccines, and genetic materials in
regulated and targeted form. This review highlights current developments and challenges in chitosan-
mediated nano therapies associated with AMD.